NLRP3 and inflammatory bowel disease: The administration of CB2R agonist HU308 activation inhibits NLRP3 inflammasome activation and induces autophagy activation in intestinal macrophages to reduce the severity of DSS-induced colitis in mice, and the protective effect on IBD was mediated by the autophagy-related pathway AMPK-mTOR-p70S6K signaling (147).